By Former drug company executive Martin Shkreli and his lead attorney Benjamin Brafman arrive at U.S. District Court for the fourth day of jury deliberations in his securities fraud trial in the Brooklyn borough of New York City, U.S., August 3, 2017.
Amr Alfiky | Reuters
The Supreme Court on Monday rejected a bid by notorious ‘pharma bro’ Martin Shkreli to hear his appeal of a $64 million financial penalty on the fraudster for blocking competition to a life-saving drug whose price he had raised by more than $700 per pill.
Shkreli’s request that the Supreme Court take his appeal of federal court decision was his last chance to overturn the penalty related to the drug Daraprim.
The Supreme Court in rejecting that request did not explain its reason for doing so. There were no noted dissents by any justice to the decision.
Shkreli gained national infamy in 2015 when his drug company hiked the price of Daraprim by more than 4,000%. The drug is used to treat parasitic infections in pregnant women, babies, people with HIV and others.
This is breaking news. Please refresh for updates.
